All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
Immunochemotherapy followed by autologous hematopoietic stem cell transplant (auto-HSCT) improves the median progression-free survival (PFS) of patients with mantle cell lymphoma (MCL). However, all regimens evaluated so far have been associated with late disease recurrences. In the randomized, phase II trial CALGB (Alliance) 50403, Lawrence D. Kaplan and colleagues investigated whether the addition of bortezomib following high-dose cytarabine-etoposide-rituximab (EAR) stem cell mobilization, high-dose cyclophosphamide-carmustine-etoposide (CBV) autografting, and post-transplant rituximab, could further improve outcomes in patients with MCL. The efficacy and safety results of the study were published in the American Journal of Hematology.1
Table 1. Adverse events
AEs, adverse events; BC, bortezomib consolidation; BM, bortezomib maintenance; NE, not established |
||||
AEs |
BC group (n= 50) |
BM group (n= 52) |
P value |
|
---|---|---|---|---|
Grade 4 hematologic events, % |
42 |
31 |
NE |
|
Non-hematologic events, % Grade 3 Grade 4 Grade 5 |
42 6 2 |
38.5 8 0 |
NE NE NE |
|
Common adverse events, % Neutropenia (Grade ≥ 3) Thrombocytopenia (Grade ≥ 3) Peripheral sensory neuropathy (Grade ≥ 2) Fatigue (Grade ≥ 2) |
54 32 44 40 |
42 17 25 31 |
0.32 0.11 0.06 0.41 |
|
Withdrawal due to AEs, % |
28 |
13 |
0.09 |
|
Table 2. Best response to bortezomib consolidation and maintenance before and after randomization
BC, bortezomib consolidation; BM, bortezomib maintenance; CR, complete response; CRu, complete response unconfirmed; NA, not assessed; PR, partial response; SD, stable disease |
||||
|
BC (n= 50) |
BM (n= 52) |
||
---|---|---|---|---|
Randomization |
Before |
After |
Before |
After |
Best response, % CR CRu PR SD NA |
38 10 48 2 2 |
70 8 20 0 2 |
38.5 21.2 34.6 5.8 0 |
59.6 21.2 17.3 1.9 0 |
Outcome comparison between CALGB 50403 and 59909
The study results demonstrate improved outcomes with the use of bortezomib after transplantation in both conditioning and maintenance settings, especially in patients who achieved MRD negativity after induction. Patients in this study had significantly longer PFS than those on the GALGB 59090 study, strengthening the evidence of BC or BM benefit after auto-HSCT. Both treatment schedules were tolerable. However, the authors of the study draw attention to the considerable toxicity in particular, fatigue and peripheral neuropathies, which for many patients may have already been present as a result of prior therapy and transplant, can significantly affect quality of life.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox